Market Overview

Abzena Signs Protein Engineering Agreement with NYU Langone Health


Abzena plc (AIM: ABZA, ‘Abzena'), the life sciences group providing
services and technologies to enable the development and manufacture of
biopharmaceutical products, has entered into a master service agreement
with one of America's leading academic medical centres, NYU Langone
Health (New York, US). The agreement, for protein engineering and drug
discovery services, will help NYU Langone's drug discovery accelerator,
the Office of Therapeutics Alliances (OTA), to develop novel
biopharmaceutical therapeutics.

The first project under this master agreement centres around the
development of a novel biopharmaceutical being developed by NYU OTA for
the treatment of severe autoimmune disease. Abzena will provide
integrated development support from its bioassay, immunology and protein
engineering groups.

NYU School of Medicine is one of the USA's top-ranked medical schools.
An integral part of NYU Langone Health, the School of Medicine at its
core is committed to improving the human condition through medical
education, scientific research, and direct patient care.

Dr. Campbell Bunce, SVP, Scientific Operations, Abzena commented:

"It's fantastic that our expertise and integrated offering across our
biology group is being used in the development of another promising

"This agreement represents another example of Abzena supporting
exciting drug candidates from academic groups, utilising not just our
services but also our significant biologics know-how."

Dr. Nadim Shohdy, Assistant Dean and Director, Therapeutics
Alliances, NYU Langone commented:

"We are very excited to execute both the master agreement, and to
launch this inaugural project with Abzena.

"This partnership will augment NYU Langone's access to deep biologics
capabilities and expertise to further enhance OTA's mission to translate
the research of our faculty into therapeutic products that help

Notes to editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary
services to enable the development and manufacture of biopharmaceutical

The term ‘ABZENA Inside' is used by Abzena to describe
products that have been created using its proprietary technologies and
are being developed by its partners, and include Composite Human
Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has
the potential to earn future licence fees, milestone payments and
royalties on ABZENA Inside products.

Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):

  • Biology research studies, including immunogenicity assessment of
    candidate biopharmaceutical products and bioassay development;
  • Protein engineering to create humanized antibodies and deimmunised
    therapeutic proteins;
  • Cell line development for the manufacture of recombinant proteins and
  • Contract process development and GMP manufacture of
    biopharmaceuticals, including monoclonal antibodies and recombinant
    proteins for preclinical and clinical studies;
  • Contract synthetic chemistry and bioconjugation research services
    focused on antibody-drug conjugates (ADCs);
  • Proprietary site-specific conjugation technologies and novel payloads
    for ADC development;
  • GMP manufacturing of ADC linkers, payloads & combined linker-payloads;
  • GMP analytical services for biopharmaceutical manufacturing projects.

For more information, please see

About NYU Office of Therapeutics Alliances and Office of Industrial

The NYU Office of Therapeutics Alliances (OTA) was created in 2013 to
accelerate and de-risk drug discovery projects developed at NYU School
of Medicine towards partnerships with investors, biopharma, and
non-profits. The NYU Office of Industrial Liaison (OIL) promotes the
commercial development of NYU discoveries and actively seeks commercial
partners for licensing and research collaborations. Over the past ten
years NYU has ranked first among all universities in income from
technology licensing.

For more information, please visit and

View Comments and Join the Discussion!